Aug. 19 at 5:32 PM
$MYGN
Fundamentals strengthening, institutions loading, chart bottomed. The setup is real.
• Barclays 13G: 5.31% stake filed post-Q2 (nearly 5M shares!)
• Q2 beat: FY25 rev raised to
$818–828M, GM ~70%, adj. EBITDA back positive
• Oncology volumes +10% y/y, gross margins holding firm
• New
$200M OrbiMed credit line → liquidity secured through 2030
• GeneSight still growing despite UNH cuts; 3 new clinical submissions targeting UNH review this fall
• CA Medicaid, multiple Blues, and other payers added in Q2
• Trades <1× fwd sales with better margins than most diagnostics peers
• Technicals: Capitulation low held
$3.90, breakout attempt building above
$6.90 →
$7.50–8.20
• If Q3 confirms,
$9–10 is not moonboy—it’s just a rerate
📉 Shorts yelling “joke” while institutions keep buying. Let them talk—volume speaks louder.
$MYGN
